12 January 2024
12 January 2024
Dermavant will include these findings in an upcoming supplemental new drug application (sNDA) submission, which is expected in Q1 2024.
The trial’s primary efficacy goal involves a modified win ratio of various clinically relevant evaluation at 52 weeks.
Participants did not experience any serious adverse events or rejection in the Phase Ia trial, which investigated the HIV candidate together with antiretroviral therapy.
Nexalin is engaging with the FDA to plan clinical trials to investigate the HALO Clarity device as an at-home treatment for a variety of mental health conditions.
Mirati filed a marketing authorisation application to the EMA for Krazati for patients within this indication in May 2022.
The new TMS approach increases the number of neurons activated during therapy for neurological disorders.
The study found that those identifying as ethnic minorities experienced a higher rate of infection.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
